92015-24-2

Usage

Uses

Used in Pharmaceutical Industry:
2-(3-chlorophenyl)-2-methylpropan-1-amine is used as a chemical intermediate for the preparation of pyrimidinediones, which are antagonists of L-type calcium channels (LTCC). These compounds have potential therapeutic applications in the treatment of Parkinson's disease, as they may help regulate the activity of L-type calcium channels, thereby modulating neuronal function and potentially alleviating symptoms associated with the disorder.

Upstream product

• 1529-41-5 3-chloro-benzeneacetonitrile 
• 64798-33-0 2-(3-chloro-phenyl)-2-methyl-propionitrile 

Downstream Products

• 1440519-53-8 [2-(3-chlorophenyl)-2-methylpropyl]carbamic acid methyl ester 

Relevant academic research and scientific papers

Structure-activity relationship of N,N′-disubstituted pyrimidinetriones as CaV1.3 calcium channel-selective antagonists for Parkinson's disease

CaV1.3 L-type calcium channels (LTCCs) have been a potential target for Parkinson's disease since calcium ion influx through the channel was implicated in the generation of mitochondrial oxidative stress, causing cell death in the dopaminergic neurons. Selective inhibition of CaV1.3 over other LTCC isoforms, especially CaV1.2, is critical to minimize potential side effects. We recently identified pyrimidinetriones (PYTs) as a CaV1.3-selective scaffold; here we report the structure-activity relationship of PYTs with both CaV1.3 and CaV1.2 LTCCs. By variation of the substituents on the cyclopentyl and arylalkyl groups of PYT, SAR studies allowed characterization of the CaV1.3 and Ca V1.2 LTCCs binding sites. The SAR also identified four important moieties that either retain selectivity or enhance binding affinity. Our study represents a significant enhancement of the SAR of PYTs at CaV1.3 and CaV1.2 LTCCs and highlights several advances in the lead optimization and diversification of this family of compounds for drug development.

NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4? R5, R6, A1, A2, A3, A4, A5 and n are as described herein,compositions including the compounds and methods of using the compounds as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrom.